Exploring differences in adverse symptom event grading thresholds between clinicians and patients in the clinical trial setting

被引:37
|
作者
Atkinson, Thomas M. [1 ]
Rogak, Lauren J. [2 ]
Heon, Narre [2 ]
Ryan, Sean J. [2 ,3 ]
Shaw, Mary [1 ]
Stark, Liora P. [1 ]
Bennett, Antonia V. [4 ]
Basch, Ethan [2 ,4 ]
Li, Yuelin [1 ]
机构
[1] Mem Sloan Kettering Canc Ctr, Dept Psychiat & Behav Sci, 641 Lexington Ave,7th Floor, New York, NY 10022 USA
[2] Mem Sloan Kettering Canc Ctr, Dept Epidemiol & Biostat, 485 Lexington Ave,2nd Floor, New York, NY 10017 USA
[3] CUNY, New York, NY 10021 USA
[4] Univ North Carolina Chapel Hill, Chapel Hill, NC USA
基金
美国国家卫生研究院;
关键词
Patient-reported outcomes; Adverse events; Clinical trials; Clinician-patient agreement; Item response theory; Neoplasms; COMMON TERMINOLOGY CRITERIA; REPORTED OUTCOMES; PRO;
D O I
10.1007/s00432-016-2335-9
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Symptomatic adverse event (AE) monitoring is essential in cancer clinical trials to assess patient safety, as well as inform decisions related to treatment and continued trial participation. As prior research has demonstrated that conventional concordance metrics (e.g., intraclass correlation) may not capture nuanced aspects of the association between clinician and patient-graded AEs, we aimed to characterize differences in AE grading thresholds between doctors (MDs), registered nurses (RNs), and patients using the Bayesian Graded Item Response Model (GRM). From the medical charts of 393 patients aged 26-91 (M = 62.39; 43% male) receiving chemotherapy, we retrospectively extracted MD, RN and patient AE ratings. Patients reported using previously developed Common Terminology Criteria for Adverse Events (CTCAE) patient-language adaptations called STAR (Symptom Tracking and Reporting). A GRM was fitted to calculate the latent grading thresholds between MDs, RNs and patients. Clinicians have overall higher average grading thresholds than patients when assessing diarrhea, dyspnea, nausea and vomiting. However, RNs have lower grading thresholds than patients and MDs when assessing constipation. The GRM shows higher variability in patients' AE grading thresholds than those obtained from clinicians. The present study provides evidence to support the notion that patients report some AEs that clinicians might not consider noteworthy until they are more severe. The availability of GRM methodology could serve to enhance clinical understanding of the patient symptomatic experience and facilitate discussion where AE grading discrepancies exist. Future work should focus on capturing explicit AE grading decision criteria from MDs, RNs, and patients.
引用
收藏
页码:735 / 743
页数:9
相关论文
共 50 条
  • [21] Differences between randomized clinical trial patients and real-world initiators of liraglutide
    Knudsen, Jakob S.
    Thomsen, Reimar W.
    Pottegard, Anton
    Baggesen, Lisbeth M.
    Knop, Filip
    Sorensen, Henrik T.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2018, 27 : 487 - 487
  • [22] Issues Impacting Adverse Event Frequency and Severity: Differences Between Randomized Phase 2 and Phase 3 Clinical Trials for Lasmiditan
    Kudrow, David
    Krege, John H.
    Hundemer, Hans P.
    Berg, Paul H.
    Khanna, Rashna
    Ossipov, Michael H.
    Pozo-Rosich, Patricia
    HEADACHE, 2020, 60 (03): : 576 - 588
  • [23] DIFFERENCES IN POST-ERCP ADVERSE EVENT RATES BETWEEN POST-LIVER TRANSPLANT PATIENTS AND PATIENTS WITH NATIVE HEPATOBILIARY ANATOMY
    Catron, Tom D.
    Shipley, Lindsey
    Johnson, Dane
    Mitchell, Rachell
    Harrison, Devin S.
    Baig, Kondal Kyanam Kabir
    Shoreibah, Mohamed G.
    Ahmed, Ali M.
    GASTROINTESTINAL ENDOSCOPY, 2019, 89 (06) : AB211 - AB212
  • [24] Clinical Symptom Differences Between Mild and Severe COVID-19 Patients in China: A Meta-Analysis
    He, Xiaobo
    Cheng, Xiao
    Feng, Xudong
    Wan, Hong
    Chen, Sihan
    Xiong, Maoming
    FRONTIERS IN PUBLIC HEALTH, 2021, 8
  • [25] Brazilian clinical trial of uniform multidrug therapy for leprosy patients - the correlation between clinical disease types and adverse effects
    Goncalves, Heitor de Sa
    de Andrade Pontes, Maria Araci
    Buehrer-Sekula, Samira
    Cruz, Rossilene
    Almeida, Paulo Cesar
    Amaral de Moraes, Maria Elisabete
    Penna, Gerson Oliveira
    MEMORIAS DO INSTITUTO OSWALDO CRUZ, 2012, 107 : 74 - 78
  • [26] Online monitoring of patient self-reported adverse events in early phase clinical trials: Views from patients, clinicians, and trial staff
    Kennedy, Fiona
    Shearsmith, Leanne
    Ayres, Michael
    Lindner, Oana C.
    Marston, Lewis
    Pass, Alison
    Danson, Sarah
    Velikova, Galina
    CLINICAL TRIALS, 2021, 18 (02) : 168 - 179
  • [27] Cardiovascular adverse events in oncology trials: understanding and appreciating the differences between clinical trial data and real-world reports
    Ewer, Michael S.
    Herson, Jay
    CARDIO-ONCOLOGY, 2022, 8 (01)
  • [28] Cardiovascular adverse events in oncology trials: understanding and appreciating the differences between clinical trial data and real-world reports
    Michael S. Ewer
    Jay Herson
    Cardio-Oncology, 8
  • [29] REVIEWING ADVERSE DRUG EVENT REPORTING BETWEEN RANDOMIZED CLINICAL TRIAL DATA AND REAL WORLD POST MARKET DATA FOR SORAFENIB AND SUNITINIB
    Grothen, A. E.
    Rivera, D. R.
    VALUE IN HEALTH, 2018, 21 : S14 - S14
  • [30] Trial participation as a determinant of clinical outcome: Differences between trial-participants and Every Day Clinical Care patients in the field of interventional cardiology
    de Boer, Sanneke P. M.
    van Leeuwen, Maarten A. H.
    Cheng, Jin M.
    Oemrawsingh, Rohit M.
    van Geuns, Robert-Jan
    Serruys, Patrick W. J. C.
    Boersma, Eric
    Lenzen, Mattie J.
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2013, 169 (04) : 305 - 310